Takeda Pharmaceutical Company Limited Q4 FY2025 earnings call

• Leadership Transition & Governance

  • Outgoing CEO Christoph Weber completed 12 years of tenure, having transformed Takeda into a focused, global R&D-driven biopharma leader with a strong late-stage pipeline. Incoming CEO Julie Kim will formally assume the role in June 2026, after a planned multi-year transition.
  • A new executive team was established in FY25Q4, with organizational changes including reduced management layers, streamlined centralized corporate functions, and expanded use of data/AI to increase speed and efficiency.
  • Six long-serving external board members will retire; three new independent directors with expertise in U.S. healthcare, Asia Pacific governance, and global pharma R&D are proposed for approval at the June AGM to align board composition with future growth needs.

• Strategic Growth Framework: Two Horizons

  • Horizon 1 (Transform for Growth, 2-3 years): Prioritize successful commercial launch of the three near-term late-stage assets, advance the broader late-stage pipeline, maintain resilience of core in-line brands, and deliver organizational efficiency improvements to free up growth capital. The goal is to return to revenue growth as new launches scale, protect core operating margins, reduce leverage, and support the existing dividend policy.
  • Horizon 2 (Growth Acceleration, mid-to-long term): Maximize value of the new cohort of blockbuster launched products, execute additional launches from the deep late-stage pipeline, and expand margins through a leaner cost structure, delivering sustained revenue growth and improved capital efficiency.

• R&D & Pipeline Progress

  • FY25 delivered positive phase 3 results for three near-term launch assets: Oveporexfin (narcolepsy type 1), Risvertide (polycythemia vera), and Zazocitinib (plaque psoriasis). Positive pivotal data was also achieved for TAC881 (subcutaneous immunoglobulin for primary immunodeficiency).
  • Phase 3 studies were initiated for L-Retrocept (anemia-associated MDS) and mezagidimab (IgA neuropathy). Strategic partnerships, including the oncology collaboration with InnoVent Biologics for TAC928 and TAC921, expanded long-term pipeline depth. Takeda now holds its most robust late-stage pipeline in company history.
  • Key upcoming milestones: Oveporexfin and Risvertide FDA approval decisions expected by August 2026; Zazocitinib approval targeted in H1 2027; phase 2 data for TAC360 (orexin-2 agonist for narcolepsy type 2) expected late 2026; regulatory submissions for TAC881 planned for 2026.

• Operational Efficiency

  • The prior enterprise-wide efficiency program completed with ~300 billion yen in gross annualized savings over two years, offsetting LOE headwinds and freeing up investment for pipeline and launches.
  • A new transformation program aligned with the organizational restructuring will impact ~4,500 roles in FY26, with an expected 170 billion yen restructuring charge. The program is targeted to deliver 100 billion yen in gross savings in FY26 and over 200 billion yen in annualized gross savings by FY28, with savings reinvested into new product launches and pipeline development.

Growth and launch products overall: Represent over 50% of total core revenue, grew 4.5% at constant exchange rates (CR).

• Gastroenterology (GI) / Immunology: Entivio grew 4.2% at CR (slightly below the 6% forecast), remains the #1 IBD brand in the U.S. Growth is pressured by ongoing pricing pressure and intensifying late-line competition.
• Rare Diseases & Plasma-Derived Therapies (PDT): Overall PDT grew 1.9% at CR, a moderation from prior years. Takeda's Texairo was roughly flat year-over-year (strong international growth offset by new U.S. competition). Immunoglobulin (IG) grew 4.1% at CR (slightly below forecast), with global industry supply increases creating near-term downward price pressure, but subcutaneous IG products continued double-digit growth. Albumin declined 2.1% at CR, impacted by lower Chinese demand from government cost containment measures.
• Oncology: Frisacla grew 14.6% at CR, in line with forecast, driven by ongoing global expansion.
• Vaccines: Cutanga grew 10.7% at CR, below forecast due to a delayed Brazilian contract signing and lower dengue outbreak incidence versus the prior year.
• Mature/LOE Portfolio: Generated ~150 billion yen in LOE-related revenue headwinds in FY25, driving the overall 2.6% core revenue decline at CR.

• FY2026 Financial Guidance

  • Core revenue: Expected to see a low single-digit percentage decline at constant exchange rates. On an actual FX basis (assuming 156 yen/USD and 182 yen/EUR), core revenue is projected to increase 3% to 4.64 trillion yen. LOE headwinds will be significantly smaller than in FY25, with new launch contribution muted in FY26 as launches occur in the second half of the calendar year, and accelerating from FY27 onward.
  • Core operating profit: Expected to decline 5% to 8% at CR, or a 1.1% decline on an actual FX basis to 1.16 trillion yen. The decline reflects planned upfront investment in new product launches and late-stage pipeline development, partially offset by 100 billion yen in transformation program savings.
  • Reported operating profit: Expected to increase 2.7% to 420 billion yen, as the full-year benefit of ended Vyvanse amortization is partially offset by FY26 transformation restructuring costs.
  • Core EPS: Expected to decline in the mid-teens percentage, a steeper decline than core operating profit due to the favorable one-time tax position that boosted FY25 EPS.
  • Adjusted free cash flow: Expected in the range of 650 billion yen to 750 billion yen.
  • Dividend: Consistent with the progressive dividend policy, the annual dividend will be increased to 204 yen per share.

• Long-Term Financial Guidance

  • Core operating profit is projected to return to growth by FY2027 at the end of Horizon 1, with growth rates dependent on new product uptake.
  • Deleveraging will continue toward the target 2.0x adjusted net debt to adjusted EBITDA ratio, with 500 billion yen in maturing debt to be repaid in FY26 using existing cash and operating cash flow, no long-term refinancing planned.
  • Core operating profit margin is targeted to expand to the low-to-mid 30% range in Horizon 2, driven by a series of successful new product launches and a streamlined stable cost base.
  • Management will outline full long-term growth ambitions and a strategic roadmap through the end of the decade at a capital markets day later in FY26.

• Mature portfolio loss of exclusivity (LOE) continues to create near-term top-line headwinds, with LOE impact only expected to shrink materially after FY25.
  • Core in-line brands face ongoing pricing pressure, competitive entry, and biosimilar challenges: Entivio faces new biosimilar filings in Europe that will require patent defense; immunoglobulin faces near-term industry oversupply and downward price pressure; albumin faces Chinese government demand containment measures.
  • New product launch success and uptake depend on regulatory approval timelines, physician adoption, and competitive dynamics, with growth trajectory uncertain until launches are well established.
  • R&D progression carries inherent clinical risk, with success of pipeline assets (including pipeline extension and indication expansions for launched new assets) not guaranteed.
  • The transformation program involves restructuring charges and workforce impacts, with execution risk related to delivering targeted cost savings while maintaining operational focus on launch execution.

Q: Is core operating profit flat or growing in 2027 and beyond after the Horizon 1 investment period? When will Phase 2 data for TAC360, the next-generation orexin agonist, be available?

A: Management projects core operating profit will return to growth starting in 2027, with the specific growth rate dependent on the uptake of newly launched products. For TAC360, Phase 2b adaptive dose-finding studies are progressing rapidly, with data expected to be shared later in 2026, and potential presentation at the World Sleep conference in September.

Q: What are the specific timelines for Horizon 1 and 2, what top-line CAGR is targeted for Horizon 2, and what are the downside risks to the plasma-derived therapies business?

A: Horizon 1 is a 2-3 year timeframe, with specific end timing dependent on new launch trajectories, and full long-term growth details will be shared at the upcoming FY26 capital markets day. For plasma products, the Chinese demand slowdown for albumin is expected to rebound over time, and current immunoglobulin oversupply is a normal cyclical market correction. Mid-single-digit IG growth and a return to stabilized albumin growth are expected, with all current market risks already incorporated into baseline projections.

Q: Will plasma-derived therapies remain a core contributor to Takeda's growth in Horizon 2, and how does Zazocitinib's no-fasting advantage position it against competing oral psoriasis therapies?

A: Yes, PDT is expected to contribute to Horizon 2 growth, supported by new pipeline assets like TAC881 that reinforce Takeda's leadership in subcutaneous immunoglobulin. Zazocitinib differentiates itself through three key advantages: rapid efficacy starting at week 4, durable efficacy out to 60 weeks, and no fasting requirements that removes a real-world adherence barrier that could reduce competitor efficacy in clinical practice.

Q: What is the breakdown of FY26 transformation savings between SG&A and R&D, and does Zazocitinib require TB testing like some competitor oral psoriasis treatments?

A: Most FY26 transformation savings will come from SG&A; R&D spending will increase in FY26 to support pipeline investment and launch preparation, with overall SG&A actually declining slightly at constant exchange rates even after including launch preparation costs. No TB reactivation has been observed in Zazocitinib clinical trials, and TB testing is a standard routine procedure for dermatologists treating psoriasis, so it is not expected to be a meaningful adoption hurdle.

Q: Are Oveporexfin and Risvertide revenues included in the FY26 forecast, and when will Takeda reach the 2.0x net leverage target, and what capital allocation flexibility will that provide?

A: Yes, first-year revenues for both assets are included in the FY26 forecast, but individual product forecasts are not disclosed publicly. Deleveraging is on track toward the 2.0x target, supported by strong steady free cash flow, but no specific end timing is provided. Once leverage reaches the target, Takeda will have increased flexibility to pursue selective incremental growth investments while maintaining capital allocation discipline.